The July/August 2016 issue of NeuroPerspective provides the midyear review/preview of 2016, and a comprehensive review of therapeutic programs in the field of Migraine. 2016 has thus far seen a dramatic contraction in institutional funding for CNS programs, and an even more striking lack of partnering. Some of this is due to macro-economic factors, the destabilizing anxiety around bizarre events in US politics, and the almost equally astounding headlines around the UK’s Brexit. The midyear issue assesses the fiscal landscape in detail (‘A Lost Year?‘), while cataloguing some of the major R&D events of 1H:16. There were disappointments from Biogen’s opicinumab, Neuren‘s trofinetide, and Marinus‘ ganaxolone, to name three, while there was something of a shorter list of upside surprises, with Minerva‘s clinical trial results standing out. The FDA was more erratic than usual, delivering on a one-trial approval for Nuplazid, while displaying flawed judgment about Lundbeck/Takeda‘s Trintellix/Brintellix, Newron‘s Xadago, and Otsuka‘s aripiprazole-chip combination drug. There are a number of clinical events upon which the sector psychology of 2H:16 will depend, with nothing looming larger than the results of the latest Phase III for solanezumab. TauRx‘s pending Alzheimer’s data, and Parkinson’s results from MedGenesis, are longshots that could turn around, or more likely, intensify, the sense of gloom around the neuro sector. Capsule summaries of events and prospects, along with critical analysis where warranted, are provided for 121 companies.
The second part of the issue provides NIR’s review of Migraine. This is considerably more positively toned than is the tenor of the sector as a whole, because the phalanx of CGRP targeting drugs, particularly the clinically advanced injectible antibodies, is likely to offer an entirely new and more efficacious approach to the prevention of migraine, rather than relying upon posthoc interception. The CGRP and CGRP-R antibodies from Teva/Labrys, Alder Biopharma, Lilly/Arteaus, and Amgen/Novartis are discussed, as are the earlier stage oral candidates from Teva/Heptares and Allergan (from Merck).
The July-August issue also contains commentary on tau imaging; Acadia‘s pricing of Nuplazid; the demise of Forum Pharma, and numerous other topics. A review of AC Immune, currently in the process of floating an IPO, is also included. 51 pages.Read More